Patient and Clinical Factors Associated With Response to Medications for Posttraumatic Stress Disorder

Brian R. Shiner, MD, MPH[a,b,c,*]; Jiang Gui, PhD[d]; Luke Rozema, MS[b]; Sarah L. Cornelius, MPH[b]; Vincent Dufort, PhD[b]; Paula P. Schnurr, PhD[e,f]; and Bradley V. Watts, MD, MPH[f,g]

ABSTRACT

Objective: Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have previously shown efficacy for posttraumatic stress disorder (PTSD) in randomized clinical trials. Two prior studies using Department of Veterans Affairs (VA) medical records data show these medications are also effective in routine practice. Using an expanded retrospective cohort, we assessed the possibility of differential patterns of response based on patient and clinical factors.

Methods: We identified 6,839 VA outpatients with clinical diagnoses of PTSD between October 1999 and September 2019 who initiated one of the medications and met pre-specified criteria for treatment duration and dose, combined with baseline and endpoint PTSD checklist (PCL) measurements. We compared 12-week changes in PCL score within clinical subgroups defined by sex, race and ethnicity, and military exposures, as well as comorbidities. Comorbidities were identified using *International Classification of Diseases* diagnostic codes and grouped according to major diagnostic classifications in the *Diagnostic and Statistical Manual of Mental Disorders*, Fifth Edition (eg, Psychotic Disorders, Depressive Disorders). We used a propensity score weighting approach to balance covariates among medication arms within each clinical subgroup. In our exploratory analyses using unweighted data for the overall cohort, we built penalized logistic regression models to identify covariates that predicted meaningful improvement.

Results: There were no significant differences between medications in our weighted subgroup analyses. In unweighted exploratory analyses, higher baseline PCL scores and concurrent receipt of evidence-based psychotherapy predicted meaningful improvement, while high levels of disability predicted not realizing meaningful improvement.

Conclusions: In the largest real-world study of medications for PTSD to date, we did not observe a pattern of differential response among clinical subgroups. All patients taking medications for PTSD, especially those with the highest levels of disability, should consider combined treatment with evidence-based psychotherapy.

J Clin Psychiatry 2021;82(6):21m13913

[a]National Center for PTSD, White River Junction, Vermont
[b]Veterans Affairs Medical Center, White River Junction, Vermont
[c]Departments of Psychiatry and The Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
[d]Departments of Biomedical Data Science, Community & Family Medicine, and The Dartmouth Institute for Health Policy & Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
[e]National Center for PTSD, White River Junction, Vermont
[f]Department of Psychiatry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
[g]Office of Systems Redesign and Improvement, Washington, DC
*Corresponding author: Brian R. Shiner, MD, MPH, VA Medical Center; 215 North Main St, 116D, White River Junction, VT 05009 (brian.shiner@va.gov).

Randomized controlled trials (RCTs) show that effective treatments for posttraumatic stress disorder (PTSD) include both pharmacologic and psychotherapeutic approaches.[1,2] Several individual medications have shown efficacy as PTSD treatment in placebo-controlled RCTs,[1,2] but there have not been head-to-head prospective comparisons of the most effective agents. Two prior retrospective studies using Department of Veterans Affairs (VA) data to examine 5 of these medications—fluoxetine, sertraline, paroxetine, topiramate, and venlafaxine—indicate that they are also effective in routine clinical practice.[3,4]

There is a great deal of variation among patients with PTSD in terms of demographic characteristics and comorbidities that appear to drive medication selection and may influence outcomes.[5,6] For example, patients with PTSD and comorbid pain disorders, headache disorders, and alcohol use disorder (AUD) are increasingly likely to receive anticonvulsants such as topiramate.[5] While expert opinion has focused on factors such as comorbidity in the selection of specific medications for PTSD,[7] there is a lack of definitive data to support such an approach.[8] In the absence of RCTs examining treatment effectiveness in specific clinical scenarios, retrospective studies using health care data can inform clinical decision making based on patient and clinical factors.[9]

Building on our prior work,[3,4] we conducted a retrospective comparative effectiveness study of the same 5 medications for PTSD in clinically important subgroups defined by sex, race and ethnicity, and military service characteristics, as well as comorbidities. In addition to examining these pre-identified groups, we conducted exploratory analyses to identify other potential predictors of meaningful improvement in symptoms. As there has been no prior research comparing these agents within clinical subgroups, we did not have a hypothesis. Rather, our goal was to provide clinicians with preliminary information about how to best select a medication based on demographic characteristics and comorbidities. While we did not have formal hypotheses, we expected to find differences in the pattern of response related to differences

Clinical Points
■ While expert opinion has focused on factors such as comorbidity to guide the selection of specific medications for PTSD, there is a lack of definitive data to support such an approach.
■ In a real-world study of almost 7,000 patients with PTSD, we did not observe any patterns of differential response to medications in clinical subgroups defined by demographics and comorbidities.
■ To improve their chances of meaningful symptomatic improvement, patients taking medications for PTSD should be encouraged to pursue combined treatment with evidence-based psychotherapy.

between the medications. For example, this might include superior PTSD symptom reduction in patients with comorbid headache disorders when they receive topiramate, presumably representing a synergistic effect of addressing both problems.

METHOD

Data Sources

This was a retrospective medical record review. We used the VA Corporate Data Warehouse (CDW) to identify all VA users with a clinical diagnosis of PTSD (309.81, F43.1x) from October 1, 1999–September 30, 2019. We obtained information on services use, clinical diagnoses, prescription fills, and patient-reported outcome measures (PROMs) from the CDW for these patients. This study was approved by the Veterans Institutional Review Board of Northern New England.

Cohort Selection

We identified patients who initiated a course of fluoxetine, sertraline, paroxetine, topiramate, or venlafaxine. The study sample was further restricted to those who met our criteria for adequate acute phase medication management. Patients receiving continuous treatment with sertraline, fluoxetine, paroxetine, venlafaxine, or topiramate daily for ≥ 12 weeks at an adequate dose were considered to have received an adequate medication trial (AMT). Adequate doses, which were required for the final 8 weeks only to allow for titration, were as follows: fluoxetine ≥ 20 mg, paroxetine ≥ 20 mg, sertraline ≥ 100 mg, topiramate ≥ 100 mg, and venlafaxine ≥ 150 mg. We further restricted to those who received baseline PTSD symptom measurement within 4 weeks prior to or 2 weeks after treatment initiation, received follow-up symptom measurement within 2 weeks prior to or 4 weeks after the 12-week point, and met our criterion for PTSD severity at baseline (defined below).

PTSD Symptoms

In order to maximize sample size within our clinical subgroups, we integrated 2 different versions of a PROM for PTSD, captured from up to 2 data sources within the

CDW, to obtain our baseline and follow-up symptom measurements. This included scores obtained from structured data produced by psychometric assessment software in the VA medical record and scores documented by clinicians in their treatment notes. We used a previously published natural language processing (NLP) algorithm with 98% precision in identifying the correct score and version of the PCL to abstract scores from clinical notes.[10,11] Scores abstracted from structured data and from NLP of clinical notes were integrated into a single dataset.

The two PROMs were the PTSD Checklist (PCL) versions aligned to the *Diagnostic and Statistical Manual of Mental Disorders* (*DSM*), Fourth and Fifth Editions,[12,13] which we will henceforth call the PCL-IV and the PCL-5.[14,15] Validation work shows a correlation of 0.87 between PCL versions in a large sample of Veterans.[16] We used a validated crosswalk (intraclass correlation coefficient = 0.96) to convert all values to PCL-5 scoring[17] and required a baseline severity score of ≥ 31 out of 80 to classify participants as having PTSD.[16] We did not examine individual symptomatic criteria for PTSD both because individual item scores were not available when abstracting PCL data from note text using NLP and because the PCL version scoring crosswalk we used was based on total scores. We created a covariate for whether the original score was from the PCL-IV or PCL-5 due to prior findings that venlafaxine may have superior effects on PTSD as assessed using *DSM-5*, but not *DSM-IV*, which may be a result of additional items related to negative alterations in cognitions and mood.[3] In addition to calculating continuous change from baseline to follow-up, we assessed a categorical outcome of clinically meaningful improvement, which was a decrease of 15 points or more from baseline to follow-up.[18]

Our a priori power calculations were based on a random sample of 200 patients from our first published study of the comparative effectiveness of evidence-based medications for PTSD in routine VA practice who had 5 repeated PCL measurements over their initial 8 weeks of an AMT (correlation, ρ = 0.7).[4] We modeled between group differences in effect size per 2-week period for change in PCL with a power of 80% and a Bonferroni-corrected 2-sided type I error rate of 0.005 to account for 10 potential comparisons at each time point using a generalized estimating equation. We found minimum cell sizes of 288, 104, and 41 for small, medium, and large effects (*d* = 0.3, 0.5, and 0.8, respectively). Therefore, we eliminated subgroups with less than 41 AMTs in any of the 5 medication cells, as greater effect size differences were implausible based on a prior meta-analysis of RCT results.[2]

Independent Variables

We measured 6 groups of covariates that could plausibly affect the relationship between treatment and outcome. See Table 1 for details.

Analysis

To conduct our primary analysis, we were guided by expert opinion in dividing the sample into putative clinical

It is illegal to post this copyrighted PDF on any website.

Table 1. Explanation of Covariates	
Trial characteristics	
Number of AMTs aligned with PCL measurement	AMTs of fluoxetine, paroxetine, sertraline, topiramate, or venlafaxine aligned with PCL measurement that each patient contributed to the outcomes analysis.
	AMTs of different agents could overlap or dovetail, but we required a 1-year gap in prescriptions to count as a new AMT of the same agent.
Number of prior AMTs	AMTs with or without PCL measurement between 1999 and the start of each AMT included in the outcomes analysis
Number of prior adequate PE or CPT trials[a]	Episodes in which patients received ≥ 8 sessions PE or CPT over the course of 1 year between 1999 and the start of each AMT included in the outcomes analysis
PCL timing, version, and severity	Number of days between medication start and baseline PCL, number of days from baseline PCL to follow-up PCL, number of days from 12-week point to follow-up PCL for each AMT included in the outcomes analysis, whether PCL scores were converted from the PCL-IV or originally PCL-5 scores, baseline PCL score using version 5 scoring
Concurrent treatments	Additional treatments received at the same time as an AMT associated with PCL measurement
Psychotherapy	Categorical receipt and number of sessions
PE[a]	Individual only
CPT[a]	Group and individual
Other psychotherapy	Group and individual
Medications	Categorical receipt of other antidepressants, other anticonvulsants, sedative hypnotics, opioids, atypical antipsychotics, and prazosin, as well as medications for alcohol use disorder and opioid use disorder
Primary prescribing clinician characteristics	Clinician who wrote the initial prescription for each AMT
Age	Continuous
Gender	Categorical male or female
Professional background	Eg, psychiatrist or pharmacist
Baseline patient characteristics	Demographics, military service characteristics
	Note that total VA service-connected disability was stratified into none, low (0%–60%), and high (70%–100%), representing increasing thresholds of disability and related VA benefits.
VA health service use characteristics	Assessed in the year preceding baseline PCL
Outpatient visits	Eg, visits to specialized PTSD clinics or to primary care clinics
Acute psychiatric care use	Emergency department and urgent care visits for psychiatric indications, psychiatric hospitalizations
Residential treatment	Stays in residential PTSD or substance abuse programs
Psychiatric comorbidities	Psychiatric diagnoses in the 2 years preceding the baseline PCL measurement. Comorbidities were identified using *ICD* diagnostic codes and grouped according to major diagnostic classifications in the *DSM-5* (eg, Psychotic Disorders, Depressive Disorders).

[a]Evidence-based psychotherapy use was measured with a natural language processing algorithm that classifies psychotherapy notes in individual and group delivery formats.[19]

Abbreviations: AMT = adequate mediation trial, CPT = cognitive processing therapy, PCL = PTSD Checklist, PE = prolonged exposure, PTSD = posttraumatic stress disorder, VA = US Department of Veterans Affairs.

subgroups based on sex, race and ethnicity, military service era, military exposures, and comorbidities.[7] We defined comorbidities by the presence of 2 or more outpatient diagnoses or 1 or more inpatient diagnosis in the year prior to medication initiation. We repeated 3 analytic steps described below separately for each clinical subgroup. As point of reference for subgroup results, we also conducted analyses in the overall group.

The first step in our primary analysis was to account for differences in covariate profile among trials of each of the 5 medications. We used the RAND Toolkit for Weighting and Analysis of Nonequivalent Groups (TWANG).[20] The TWANG package supports causal modeling of observational data through the estimation and evaluation of propensity scores and associated weights. In our application, the propensity score represented the probability that a particular trial would be of each medication.[21] We estimated propensity scores with multinomial logistic regression using generalized booster effects,[22] in which the dependent variable is an indicator for each of the 5 medications and the independent variables are an antiparsimonious specification of variables that have a plausible correlation with the outcome (ie, our 6 groups of covariates).[21,22] Using these propensity scores, we weighted

participants in order to balance the covariate distributions across medications.

The second step in our primary analysis was to compare continuous and categorical outcomes among the 5 medications with weighted regression analyses, using medication received as the sole independent variable. In general, weighted means can have greater sampling variance than unweighted means. Therefore, we used survey commands, which account for the weights, to perform the outcomes analyses when comparing the weighted medication groups. These weighted medication groups were defined by the inverse of the propensity scores and adjusted covariates unbalanced at the $P < .01$ level after TWANG weighting. In balancing our extensive list of covariates, a Bonferroni correction would indicate a corrected α of $P < .001$. However, we conservatively maintained an α threshold of $P < .01$ for significant differences to avoid type II error. For our continuous outcome of change in total PCL score, we used weighted linear regression analysis, whereby the coefficient of the variable tests the hypothesis that each of the 5 psychotropic medications has the same mean change from baseline to follow-up. For our categorical outcome of clinically meaningful improvement, we used weighted logistic regression analysis, whereby the coefficient of the

Table 2. Characteristics of New Trials of Adequate Dose and Duration Evidence-Based Medications for PTSD, With Aligned PCL Measurement

Characteristic	Value
Number of AMTs with PCL data patients contribute, % (n)	
1	96.9 (6,630)
2+	3.1 (423)
Number of prior AMTs with or without PCL data, % (n)	
0	80.7 (5,692)
1	15.2 (1,069)
2+	4.1 (292)
Number of prior adequate PE or CPT trials, % (n)	
0	92.5 (6,521)
1	7.1 (498)
2+	0.5 (34)
PCL timing, version, and severity, mean (SD)	
Days from AMT start to baseline PCL	8.4 (7.2)
Days from baseline PCL to follow-up PCL	92.8 (16.0)
Days from AMT week 12 to follow-up PCL	10.1 (7.9)
Baseline score converted from PCL-IV	63.6 (4,486)
Follow-up score converted from PCL-IV	60.4 (4,262)
Baseline PCL score using version 5 scoring	55.5 (12.1)

Abbreviations: AMT = adequate medication trial (12 or more weeks of fluoxetine, sertraline, topiramate, paroxetine, or venlafaxine at required dose at a minimally adequate dose), CPT = cognitive processing therapy, PCL = PTSD Checklist, PE = prolonged exposure, PTSD = posttraumatic stress disorder.

Table 3. Characteristics of New Trials of Adequate Dose and Duration Evidence-Based Medications for PTSD (n = 6,839)

Characteristic	Value
Concurrent treatment	
Any PE, % (n)	6.9 (483)
Sessions of PE, mean (SD)	4.4 (3.3)
Any Individual CPT, % (n)	20.1 (1,419)
Sessions of individual CPT, mean (SD)	4.9 (3.4)
Any Group CPT, % (n)	7.4 (519)
Sessions of group CPT, mean (SD)	5.5 (4.6)
Any non-PE/CPT individual therapy, % (n)	36.5 (2,577)
Sessions of non-PE/CPT individual therapy, mean (SD)	1.6 (3.4)
Any non-CPT group therapy, % (n)	52.4 (3,698)
Sessions of Non-CPT Group Therapy, mean (SD)	8.2 (10.6)
Any non-F/S/P/V antidepressant, % (n)	45.2 (3,187)
Any non-topiramate anticonvulsant, % (n)	21.7 (1,528)
Any sedative/hypnotics, % (n)	25.9 (1,825)
Any opioid, % (n)	17.8 (1,257)
Any atypical antipsychotic, % (n)	17.3 (1,219)
Any prazosin, % (n)	33.3 (2,348)
Any medications for alcohol use disorder, % (n)	15.9 (1,124)
Any medications for opioid use disorder, % (n)	4.3 (301)
Primary prescribing clinician characteristics	
Age, mean (SD)	49.5 (11.9)
Women, % (n)	42.1 (2,967)
Psychiatrist, % (n)	54.6 (3,849)
Other physician, % (n)	16.0 (1,128)
Mental nurse practitioner or physician assistant, % (n)	13.8 (973)
Other nurse practitioner or physician assistant, % (n)	11.2 (789)
Pharmacist, % (n)	4.0 (281)
Patient characteristics at baseline	
Age, mean (SD)	40.1 (12.0)
Women, % (n)	13.1 (924)
Married, % (n)	55.2 (3,892)
Rural, % (n)	35.1 (2,475)
White non-Hispanic, % (n)	66.1 (4,662)
Black non-Hispanic, % (n)	15.8 (1,117)
Hispanic, % (n)	11.1 (780)
Post-9/11 veteran, % (n)	71.8 (5,065)
Vietnam veteran, % (n)	6.2 (434)
Combat exposure, % (n)	65.1 (4,589)
Sexual trauma while in military, % (n)	12.3 (864)
VA disability level 70% or greater, % (n)	55.5 (3,914)
Service use characteristics in the 1 year preceding baseline	
Any PTSD outpatient clinical team visits, % (n)	43.3 (3,055)
Number of PTSD outpatient clinical team visits, mean (SD)	5.0 (13.6)
Any outpatient mental health visits, % (n)	98.4 (6,942)
Number of outpatient mental health visits, mean (SD)	27.1 (48.7)
Any outpatient substance abuse visits, % (n)	16.9 (1,190)
Number of outpatient substance abuse visits, mean (SD)	4.8 (21.9)
Any outpatient primary care visits, % (n)	89.9 (6,337)
Number of outpatient primary care visits, mean (SD)	5.4 (6.3)
Any ED visits for psychiatric indication, % (n)	17.5 (1,232)
Number of ED visits for psychiatric indication, mean (SD)	1.0 (1.4)
Any acute inpatient mental health treatment, % (n)	11.9 (840)
Days of acute inpatient mental health, mean (SD)	11.7 (16.3)
Any residential PTSD treatment, % (n)	2.9 (202)
Days residential PTSD treatment, mean (SD)	67.6 (42.0)
Any residential substance abuse treatment, % (n)	2.9 (206)
Days residential substance abuse treatment, mean (SD)	45.4 (40.0)
Comorbidities in the 2 years preceding baseline	
Pain disorders, % (n)	69.1 (4,876)
Headache disorders, % (n)	29.9 (2,110)
Psychotic disorders, % (n)	2.7 (188)
Bipolar mood disorders, % (n)	5.3 (373)
Depressive mood disorders, % (n)	73.3 (5,173)
Anxiety disorders, %(n)	35.2 (2,485)
Traumatic brain injury, % (n)	13.6 (959)
Alcohol use disorders, % (n)	30.0 (2,117)
Opioid use disorders, % (n)	5.5 (385)
Other substance use disorders, % (n)	17.0 (1,200)

Abbreviations: CPT = cognitive processing therapy, F/S/P/V = fluoxetine/sertraline/paroxetine/venlafaxine, FY = fiscal year, OEF/OIF/OND = Operations Enduring Freedom/Iraqi Freedom/New Dawn, PCL = PTSD Checklist, PCT = PTSD care team, PE = prolonged exposure, PTSD = posttraumatic stress disorder, VA = Department of Veterans Affairs.

variable tests the hypothesis that each of the 5 psychotropic medications results in the same percentage of patients achieving clinically meaningful improvement. *P* values were calculated from Wald test in the propensity score weighted regression models.

The third step in our primary analysis was to the potential contribution of unmeasured confounding on significant baseline to follow-up differences by calculating E-values, which indicate the minimum strength of association on the risk ratio scale that an unmeasured confounder would need to have with both the exposure and the outcome, conditional on the measured covariates, to fully explain away a specific exposure-outcome association.[23,24]

For our exploratory analyses, we conducted penalized logistic regression models to identify the strongest predictors of meaningful improvement and remission using least absolute shrinkage and selection operators (LASSO).[25] As we were interested in predictors within (rather than between) comparison groups, we used raw (rather than propensity-score weighted) covariates described in Table 1. We chose LASSO because it provides information about predictors that are most important when many covariates are available. We set the tuning parameter to select the most regularized model such that error is within 1 standard error of the cross-validated minimum. We evaluated the robustness of our feature selection using 100 bootstrapped samples. At the extreme ends of the distribution of bootstrapped replications, some features that are important in the full model are dropped by LASSO. We ran LASSO models in 6 groups: overall (including an indicator for medication received) and patients who received each of the 5 medications. We performed data management in SAS version 9.4 (SAS Institute) and statistical modeling in R version 4.0.2 (R core team).

Table 4. Weighted Outcomes: Subgroup Analyses[a]

	Fluoxetine	Paroxetine	Sertraline	Topiramate	Venlafaxine
Overall, N	2,093	889	2,399	594	1,078
Baseline PCL score, mean (SD)	55.4 (12.3)	55.8 (12.2)	55.5 (12.4)	55.3 (19.7)	55.9 (12.7)
Change in PCL, mean (SD)	−6.6 (15.0)	−5.9 (15.3)	−6.6 (15.5)	−5.2 (26.6)	−6.3 (16.1)
15-point improvement, % (n)	24.3 (513)	23.4 (206)	25.7 (638)	22.5 (123)	24.9 (264)
Men, N	1,787	798	2,158	468	918
Baseline PCL score, mean (SD)	55.4 (12.2)	55.7 (12.3)	55.6 (12.3)	54.8 (18.6)	55.9 (12.6)
Change in PCL, mean (SD)	−6.6 (14.9)	−5.9 (20.8)	−6.4 (27.8)	−4.8 (25.7)	−6.4 (22.0)
15-point improvement, % (n)	24.2 (433)	23.6 (189)	25.0 (564)	21.0 (93)	25.2 (225)
Women, N	306	91	241	126	160
Baseline PCL score, mean (SD)	55.0 (12.5)	56.2 (11.6)	55.2 (12.8)	56.9 (16.6)	56.1 (13.2)
Change in PCL, mean (SD)	−7.0 (16.2)	−6.1 (18.2)	−8.5 (25.8)	−7.0 (28.5)	−5.2 (22.5)
15-point improvement, % (n)	26.8 (80)	21.5 (17)	30.4 (74)	28.0 (30)	20.1 (39)
White non-Hispanic, N	1,391	603	1,523	380	765
Baseline PCL score, mean (SD)	54.3 (12.1)	54.6 (12.0)	54.5 (12.2)	54.5 (18.0)	54.9 (12.4)
Change in PCL, mean (SD)	−6.8 (15.2)	−5.8 (20.5)	−6.8 (27.4)	−5.8 (26.3)	−6.8 (22.5)
15-point improvement, % (n)	24.8 (350)	23.6 (143)	26.3 (416)	24.6 (88)	26.8 (202)
Black non-Hispanic, N	323	138	415	103	138
Baseline PCL score, mean (SD)	57.8 (11.6)	58.4 (13.0)	57.7 (11.9)	58.2 (18.2)	58.4 (12.6)
Change in PCL, mean (SD)	−6.0 (14.6)	−5.5 (20.5)	−6.5 (28.2)	−5.4 (29.5)	−2.7 (20.4)
15-point improvement, % (n)	22.5 (74)	20.2 (27)	24.6 (105)	25.9 (18)	16.7 (25)
Hispanic, N	231	100	270	72	107
Baseline PCL score, mean (SD)	56.5 (12.5)	58.3 (13.4)	57.7 (12.5)	56.3 (18.1)	57.7 (14.2)
Change in PCL, mean (SD)	−6.2 (16.1)	−5.7 (20.7)	−6.3 (29.1)	−1.4 (17.9)	−5.6 (24.8)
15-point improvement, % (n)	24.4 (55)	20.8 (22)	26.0 (75)	9.2 (9)	17.9 (20)
Post-9/11 veteran, N	1,491	646	1,697	466	765
Baseline PCL score, mean (SD)	55.0 (12.4)	55.3 (12.4)	55.23 (12.7)	55.1 (19.8)	55.5 (13.0)
Change in PCL, mean (SD)	−6.4 (15.0)	−6.0 (20.8)	−6.3 (27.3)	−5.5 (29.1)	−6.5 (22.3)
15-point improvement, % (n)	23.6 (354)	24.0 (155)	24.5 (440)	21.3 (92)	25.3 (191)
Combat, N	1,357	591	1,507	428	706
Baseline PCL score, mean (SD)	54.9 (12.4)	55.3 (12.4)	55.2 (12.6)	54.6 (19.2)	55.5 (13.1)
Change in PCL, mean (SD)	−6.3 (14.9)	−6.0 (21.0)	−6.3 (26.9)	−5.1 (25.3)	−6.5 (22.2)
15-point improvement, % (n)	22.8 (312)	23.5 (135)	24.5 (388)	19.3 (80)	25.2 (174)
Military sexual trauma, N	273	89	256	100	146
Baseline PCL score, mean (SD)	55.8 (12.2)	57.3 (12.8)	56.5 (12.6)	56.8 (15.2)	57.7 (12.1)
Change in PCL, mean (SD)	−7.6 (22.4)	−6.8 (20.3)	−10.2 (30.8)	−10.0 (27.0)	−7.5 (25.3)
15-point improvement, % (n)	25.7 (69)	23.3 (19)	34.4 (83)	35.7 (25)	22.9 (32)
Pain, N	1,426	612	1,575	466	797
Baseline PCL score, mean (SD)	55.8 (12.3)	56.0 (12.3)	55.9 (12.5)	55.6 (17.2)	56.2 (12.5)
Change in PCL, mean (SD)	−6.5 (14.9)	−6.0 (21.0)	−5.9 (26.7)	−4.8 (21.7)	−6.0 (22.0)
15-point improvement, % (n)	23.5 (339)	23.0 (137)	23.7 (390)	20.3 (96)	23.9 (185)
Headache, N	568	245	571	365	361
Baseline PCL score, mean (SD)	56.3 (12.6)	57.0 (13.0)	56.5 (12.5)	56.2 (18.3)	56.4 (12.8)
Change in PCL, mean (SD)	−5.4 (14.4)	−6.0 (20.4)	−5.1 (24.6)	−5.8 (25.3)	−5.8 (24.2)
15-point improvement, % (n)	19.1 (108)	23.9 (59)	20.8 (119)	22.9 (77)	25.4 (85)
Traumatic brain injury, N	230	121	298	125	185
Baseline PCL score, mean (SD)	55.4 (12.9)	57.6 (11.4)	56.0 (12.7)	57.2 (16.1)	55.4 (13.3)
Change in PCL, mean (SD)	−6.9 (14.1)	−4.3 (21.7)	−4.6 (27.0)	−6.0 (21.4)	−4.9 (23.3)
15-point improvement, % (n)	23.3 (52)	20.8 (20)	20.5 (62)	24.0 (32)	21.2 (40)
Depressive disorders, N	1,566	632	1,700	422	853
Baseline PCL score, mean (SD)	55.8 (12.1)	56.2 (12.4)	56.1 (12.5)	55.8 (18.0)	56.2 (12.6)
Change in PCL, mean (SD)	−6.5 (14.8)	−6.0 (20.1)	−6.6 (26.7)	−5.1 (25.1)	−6.3 (22.1)
15-point improvement, % (n)	24.0 (380)	22.7 (141)	25.2 (448)	22.5 (88)	24.1 (208)
Anxiety disorders, N	706	333	817	212	417
Baseline PCL score, mean (SD)	55.5 (12.1)	55.9 (12.3)	55.9 (12.5)	54.5 (16.7)	55.7 (12.7)
Change in PCL, mean (SD)	−6.3 (14.7)	−5.9 (21.5)	−7.4 (27.3)	−6.5 (23.6)	−6.5 (22.8)
15-point improvement, % (n)	23.3 (165)	25.6 (84)	28.1 (241)	24.6 (49)	25.9 (107)
Bipolar disorders, N	97	52	102	67	55
Baseline PCL score, mean (SD)	56.8 (12.8)	58.7 (13.3)	56.4 (12.8)	58.6 (13.5)	57.7 (13.8)
Change in PCL, mean (SD)	−5.8 (12.9)	−6.6 (20.1)	−9.7 (23.6)	−8.9 (21.4)	−7.1 (23.8)
15-point improvement, % (n)	18.7 (22)	24.5 (12)	34.3 (34)	31.4 (20)	30.9 (16)
Alcohol use disorder, N	619	269	722	164	343
Baseline PCL score, mean (SD)	56.6 (12.0)	57.0 (12.4)	56.6 (12.5)	55.0 (16.8)	57.3 (13.1)
Change in PCL, mean (SD)	−7.1 (16.1)	−7.0 (23.2)	−7.5 (29.1)	−4.9 (23.8)	−6.5 (23.5)
15-point improvement, % (n)	27.6 (172)	26.6 (70)	27.1 (203)	19.6 (37)	25.1 (88)
Drug use disorders, N	363	175	454	92	196
Baseline PCL score, mean (SD)	56.7 (11.9)	56.7 (13.1)	56.8 (12.3)	55.6 (18.2)	57.1 (12.7)
Change in PCL, mean (SD)	−6.6 (15.0)	−5.9 (15.3)	−6.6 (15.5)	−5.2 (26.6)	−6.3 (16.1)
15-point improvement, % (n)	24.3 (513)	23.4 (206)	25.7 (638)	22.5 (123)	24.9 (264)

[a]There were no differences at $P < .005$ in any comparison.
Abbreviations: PCL = PTSD Checklist, PTSD = posttraumatic stress disorder.

Table 5. Unweighted Predictors of Meaningful (15-Point) Improvement in PCL Score

Group	Predictor	OR (95% CI)
Overall	Number of concurrent individual CPT sessions (per unit)	1.08 (1.05–1.10)
	Baseline PCL score value (per unit)	1.02 (1.02–1.03)
	VA disability rating of 70% or greater	0.83 (0.72–0.93)
Fluoxetine	Number of concurrent PE sessions (per unit)	1.12 (1.02–1.20)
	Number of concurrent individual CPT sessions (per unit)	1.08 (1.04–1.12)
	Baseline PCL score value (per unit)	1.02 (1.01–1.03)
Sertraline	Baseline PCL score value (per unit)	1.02 (1.01–1.03)
	VA disability rating of 70% or greater	0.83 (0.68–1.00)

Abbreviations: CPT = cognitive processing therapy, PCL = PTSD Checklist, PE = prolonged exposure.

RESULTS

There were 7,053 AMTs aligned with PCL measurement, including 2,093 of fluoxetine, 889 of paroxetine, 2,399 of sertraline, 594 of topiramate, and 1,078 of venlafaxine. Roughly 3% of patients contributed more than 1 AMT with PCL measurement to the analysis (Table 2), although almost 20% of patients had 1 or more prior AMTs with or without associated PCL measurement. Most PCL scores were converted from PCL-IV values, and mean baseline symptom severity was high. While less than 10% had an adequate trial of PE or CPT prior to the start of their AMT, almost 7% received concurrent PE, over 20% received concurrent individual CPT, and over 7% received concurrent group CPT (Table 3). Patients also commonly received other antidepressants, other anticonvulsants, sedative-hypnotics, and prazosin concurrently with their AMT. Patients had a high degree of VA primary care, mental health, and substance abuse service use in the year preceding their AMT. There was generally good representation across our pre-defined demographic and diagnostic subgroups. However, cell sizes were below our sample size threshold for Vietnam Veterans and comorbid psychotic disorders. Because cell sizes were also too small for comorbid opioid use disorder, this group was combined with other non-AUD substance use disorders for a general drug use disorder category in subgroup analyses.

While there were differences among the medication treatment groups, our weighting procedure allowed us to balance covariates in the overall group and in almost all subgroup analyses. The exception was a higher percentage of non-psychiatrist physicians prescribing topiramate in the subgroup analyses for women, military sexual trauma, and headache. Therefore, this covariate was retained in the relevant subgroup analyses.

All 5 of the medications were associated with an approximately 10% improvement in PTSD symptoms in the overall analysis (Table 4). The mean improvement in total PCL score ranged from 5.2 points for the topiramate group to 6.6 points for the sertraline and fluoxetine groups; clinically meaningful improvement rates ranged from 22.5% in the topiramate group to 25.7% in the sertraline group. There were no significant differences between medication arms in our overall analysis or in our clinical subgroups at our a priori threshold for significance of $P < .005$. As there were no significant differences, there were no findings to assess with the E-value.

In our penalized regression analysis, each session of concurrent individual CPT was associated with 8% increased odds of clinically meaningful improvement, while a VA disability rating of 70% or greater was associated with 17% decreased odds of clinically meaningful improvement in the overall group (Table 5). Both PE and individual CPT sessions were associated with increased odds of clinically meaningful improvement among patients in the fluoxetine arm, and a VA disability rating of 70% of greater was associated with decreased odds of clinically meaningful improvement among patients in the sertraline arm. A higher baseline PCL score was associated with increased odds of improvement in the overall group as well as the fluoxetine and sertraline arms. No covariates predicted clinically meaningful improvement in the paroxetine, topiramate, or venlafaxine arms.

DISCUSSION

Our data do not support the idea that patient and clinical factors predict differential treatment response among effective medications for PTSD. Across all clinical subgroups, a quarter to a fifth of patients had a meaningful improvement of 15 points or more on the PCL. Our results showed extremely consistent response of PTSD to the 5 treatments across the multiple subgroups. There is meaningful heterogeneity among the treatments we examined; fluoxetine, sertraline, and paroxetine are selective serotonin reuptake inhibitors, while venlafaxine is a serotonin-norepinephrine reuptake inhibitor, and topiramate is an anticonvulsant.[26]

In our prior work using only PCL-5 data, venlafaxine was associated with superior remission rates compared to the other agents, possibly due to new items in the negative alterations in cognitions and mood cluster.[3] While it might have been reasonable to expect a signal for venlafaxine in the clinical subgroup with comorbid depression based on our prior finding, we did not see one. This may be because most PCL values in the venlafaxine arm originated from PCL-IV data, which do not represent these new items. Additionally, we did not have individual item data for all patients, as this larger analysis involved combining all possible PCL data sources. Therefore, we could not assess symptomatic remission and used a clinically meaningful improvement threshold instead. It is possible that we would have seen differences had we considered other outcomes. We were similarly disappointed in the lack of any signal for topiramate. For example, topiramate is FDA-approved for prophylaxis of migraine headaches and is also recommended for prevention of several other headache types,[27,28] yet we did not observe superior PTSD outcomes among patients receiving topiramate in the clinical subgroup with headache disorders. While we were unable to assess potentially mediating changes in

headache symptoms, it is possible that headache response is unassociated with PTSD response even if clinical trial data indicate that topiramate can be helpful in both disorders. These two examples speak more broadly to a weakness in our approach, namely that we did not include other relevant outcomes such as pain, depression, or anxiety apart from our overall PTSD symptom scale. Therefore, it remains possible that specific agents do have an advantage in populations with particular comorbidities because they provide benefit for important symptoms other than PTSD such as depression or chronic pain. Future work should include as many measures as possible of these relevant comorbidity symptoms.

Our exploratory analysis similarly did not lead to new information about which patients will have a clinically meaningful improvement to individual medications despite the inclusion of an extensive list of patient and treatment-related covariates as potential predictors. In the penalized regression model for the overall group, no indicator for medication arm emerged as a predictor. While concurrent evidence-based psychotherapy sessions emerged as a predictor of clinically meaningful improvement in the fluoxetine arm and VA disability of 70% or greater emerged as a predictor of not achieving clinically meaningful improvement in the sertraline arm, other medication groups were far smaller and there were similar predictors in the overall model. Therefore, it is unlikely that these effects are particular to individual agents. It is our belief that concurrent treatment with evidence-based psychotherapy for PTSD predicts better treatment outcomes and severe disability predicts worse outcomes across medication groups. Notably, however, we performed our exploratory analysis using unweighted data, so it is possible that patients receiving evidence-based psychotherapy or with VA disability of 70% or greater could be different in other ways that account for differences in outcomes seen in these groups. Consistent with our findings, several prior studies have found poorer PTSD treatment outcomes for patients who are service connected or in the process of applying for service connection.[29–31] One possibility is that some patients may underreport improvements due to fear of losing disability benefits,[32] and this factor could have influenced our findings.

As noted in our prior work, there are several major limitations inherent in using an uncontrolled retrospective cohort design to emulate an RCT using VA data.[3,4] The chief differences compared to an RCT are that this work was not prospective, randomized, or placebo-controlled. As a result, limitations include significant differences in concurrent treatment receipt between those with and without PCL measurement; lack of information about treatment adherence, patient preference, and expectations; and uncertainty about whether these results would apply to users of other health systems. VA patients with sufficient PCL data to contribute to outcomes analysis are generally receiving very high-intensity care compared to those without PCL data.[6] The need for such intensive care may indicate a degree of treatment resistance,[33] and our outcomes must be considered in this context. Improved clinical data collection in the VA as well as replication in other health systems could address these concerns in future studies. A new limitation particular to this analysis is that PCL measurements were combined from multiple versions of the tool in order to generate enough sample size for subgroup analyses. While the versions are well-correlated and we used a validated crosswalk, the PCL-5 includes additional items representing the contemporary case definition of PTSD that are not included in the PCL-IV. While we accounted for this by including a covariate for PCL version in our propensity weighting model, subgroup analyses using exclusively PCL-5 data may be possible in the future if the VA's effort to increase use of PROM through the measurement-based care initiative are successful.[34] Lastly, our lack of measures for severity of important and common comorbid disorders was a clear deficiency.

In conclusion, we have conducted the largest real-world study of medications for PTSD to date and did not observe a pattern of differential response among clinical subgroups. Thus, it is appropriate to question the conventional clinical wisdom that factors such as patient comorbidities can guide clinicians and patients in selecting among effective medications for PTSD. Our work continues to show that all patients taking medications for PTSD should be encouraged to pursue combined treatment with evidence-based psychotherapy.

REFERENCES

1. Jonas DE, Cusack K, Forneris CA, et al. *Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder (PTSD)*. Agency for Healthcare Research and Quality; 2013.
2. Watts BV, Schnurr PP, Mayo L, et al. Meta-analysis of the efficacy of treatments for posttraumatic stress disorder. *J Clin Psychiatry*. 2013;74(6):e541–e550.
3. Shiner B, Leonard CE, Gui J, et al. Comparing medications for *DSM-5* PTSD in routine VA practice. *J Clin Psychiatry*. 2020;81(6):20m13244.
4. Shiner B, Westgate CL, Gui J, et al. A retrospective comparative effectiveness study of medications for posttraumatic stress disorder in routine practice. *J Clin Psychiatry*. 2018;79(5):18m12145.
5. Shiner B, Westgate CL, Bernardy NC, et al.

Anticonvulsant medication use in veterans with posttraumatic stress disorder. *J Clin Psychiatry*. 2017;78(5):e545–e552.

6. Shiner B, Gui J, Leonard Westgate C, et al. Using patient-reported outcomes to understand the effectiveness of guideline-concordant care for post-traumatic stress disorder in clinical practice. *J Eval Clin Pract*. 2019;25(4):689–699.

7. Schoenfeld FB, Marmar CR, Neylan TC. Current concepts in pharmacotherapy for posttraumatic stress disorder. *Psychiatr Serv*. 2004;55(5):519–531.

8. Ipser JC, Stein DJ. Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). *Int J Neuropsychopharmacol*. 2012;15(6):825–840.

9. Shiner B, Watts BV. Invited commentary: baby steps to a learning mental health-care system-can we do the work? *Am J Epidemiol*. 2021;190(7):1220–1222.

10. Holder N, Shiner B, Li Y, et al. Cognitive processing therapy for veterans with posttraumatic stress disorder: what is the median effective dose? *J Affect Disord*. 2020;273:425–433.

11. Holder N, Shiner B, Li Y, et al. Determining the median effective dose of prolonged exposure therapy for veterans with posttraumatic stress disorder. *Behav Res Ther*. 2020;135:103756.

12. American Psychiatric Association. *Diagnostic and Statistical Manual for Mental Disorders*. Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.

13. American Psychiatric Association. *Diagnostic and Statistical Manual for Mental Disorders*. Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

14. Blevins CA, Weathers FW, Davis MT, et al. The Posttraumatic Stress Disorder Checklist for *DSM-5* (PCL-5): development and initial psychometric evaluation. *J Trauma Stress*. 2015;28(6):489–498.

15. Weathers FW, Litz BT, Herman DS, et al. The PTSD Checklist (PCL): reliability, validity, and diagnostic utility. Trauma, coping, and adaptation. International Society for Traumatic Stress Studies, 9th Annual Meeting; 1993; San Antonio, Texas.

16. Bovin MJ, Marx BP, Weathers FW, et al. Psychometric properties of the PTSD Checklist for *Diagnostic and Statistical Manual of Mental Disorders*-Fifth Edition (PCL-5) in veterans. *Psychol Assess*. 2016;28(11):1379–1391.

17. Moshier SJ, Lee DJ, Bovin MJ, et al. An empirical crosswalk for the PTSD Checklist: translating *DSM-IV* to *DSM-5* using a veteran sample. *J Trauma Stress*. 2019;32(5):799–805.

18. Lee DJ, Bovin MJ, Weathers FW, et al. Reliable Change Index and Clinically Significant Margins for the CAPS-5 and PCL-5 among Veterans. International Society for Traumatic Stress Studies, 35th Annual Meeting; 2019; Boston, MA.

19. Maguen S, Madden E, Patterson OV, et al. Measuring use of evidence based psychotherapy for posttraumatic stress disorder in a large national healthcare system. *Adm Policy Ment Health*. 2018;45(4):519–529.

20. Ridgeway G, McCaffrey DF, Morral AR, et al. *Toolkit for Weighting and Analysis of Nonequivalent Groups: A Tutorial for the TWANG Package*. RAND Corporation; 2017.

21. Stuart EA. Matching methods for causal inference: a review and a look forward. *Stat Sci*. 2010;25(1):1–21.

22. McCaffrey DF, Griffin BA, Almirall D, et al. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. *Stat Med*. 2013;32(19):3388–3414.

23. Haneuse S, VanderWeele TJ, Arterburn D. Using the E-value to assess the potential effect of unmeasured confounding in observational studies. *JAMA*. 2019;321(6):602–603.

24. VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E-value. *Ann Intern Med*. 2017;167(4):268–274.

25. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. *J Stat Softw*. 2010;33(1):1–22.

26. Asnis GM, Kohn SR, Henderson M, et al. SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations. *Drugs*. 2004;64(4):383–404.

27. Linde M, Mulleners WM, Chronicle EP, et al. Topiramate for the prophylaxis of episodic migraine in adults. *Cochrane Database Syst Rev*. 2013;(6):CD010610.

28. May A, Leone M, Afra J, et al; EFNS Task Force. EFNS guidelines on the treatment of cluster headache and other trigeminal-autonomic cephalalgias. *Eur J Neurol*. 2006;13(10):1066–1077.

29. Sripada RK, Blow FC, Rauch SAM, et al. Examining the nonresponse phenomenon: factors associated with treatment response in a national sample of veterans undergoing residential PTSD treatment. *J Anxiety Disord*. 2019;63:18–25.

30. Crawford EF, Wolf GK, Kretzmer T, et al. Patient, therapist, and system factors influencing the effectiveness of prolonged exposure for veterans with comorbid posttraumatic stress disorder and traumatic brain injury. *J Nerv Ment Dis*. 2017;205(2):140–146.

31. Goodson JT, Helstrom AW, Marino EJ, et al. The impact of service-connected disability and therapist experience on outcomes from prolonged exposure therapy with veterans. *Psychol Trauma*. 2017;9(6):647–654.

32. Walter KH, Varkovitzky RL, Owens GP, et al. Cognitive processing therapy for veterans with posttraumatic stress disorder: a comparison between outpatient and residential treatment. *J Consult Clin Psychol*. 2014;82(4):551–561.

33. Sippel LM, Holtzheimer PE, Friedman MJ, et al. Defining treatment-resistant posttraumatic stress disorder: a framework for future research. *Biol Psychiatry*. 2018;84(5):e37–e41.

34. Resnick SG, Hoff RA. Observations from the national implementation of measurement based care in mental health in the Department of Veterans Affairs. *Psychol Serv*. 2020;17(3):238–246.